Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Infliximab and adalimumab for uveitis.

Martel JN, Esterberg E, Nagpal A, Acharya NR.

Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.

PMID:
22324897
2.

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

Bawazeer A, Raffa LH, Nizamuddin SH.

Ocul Immunol Inflamm. 2010 Jun;18(3):226-32. doi: 10.3109/09273948.2010.483314.

PMID:
20482404
3.

Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.

Doycheva D, Zierhut M, Blumenstock G, Stuebiger N, Januschowski K, Voykov B, Deuter C.

Br J Ophthalmol. 2014 Apr;98(4):523-8. doi: 10.1136/bjophthalmol-2013-303935. Epub 2014 Jan 23.

PMID:
24457365
4.

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.

Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC.

J Crohns Colitis. 2011 Aug;5(4):324-31. doi: 10.1016/j.crohns.2011.02.007. Epub 2011 Mar 10.

PMID:
21683302
5.

Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up.

Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ.

Am J Ophthalmol. 2007 Dec;144(6):844-849. Epub 2007 Oct 22.

6.

A three-centre experience with adalimumab for the treatment of non-infectious uveitis.

Dobner BC, Max R, Becker MD, Heinz C, Veltrup I, Heiligenhaus A, Barisani-Asenbauer T, Mackensen F.

Br J Ophthalmol. 2013 Feb;97(2):134-8. doi: 10.1136/bjophthalmol-2011-301401. Epub 2012 Dec 4.

PMID:
23212204
7.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

8.

[Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].

Fery-Blanco C, Schwartz C, Gil H, Curlier E, Prati C, Delbosc B.

J Fr Ophtalmol. 2011 Dec;34(10):697-702. doi: 10.1016/j.jfo.2011.03.011. Epub 2011 Sep 1. French.

9.

Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.

Galor A, Perez VL, Hammel JP, Lowder CY.

Ophthalmology. 2006 Dec;113(12):2317-23. Epub 2006 Sep 25.

PMID:
16996615
10.

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P.

Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. Epub 2007 Jun 7.

PMID:
17554481
11.

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF.

Ophthalmology. 2012 Aug;119(8):1575-81. doi: 10.1016/j.ophtha.2012.02.018. Epub 2012 Apr 21.

PMID:
22525047
12.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

13.

Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.

Interlandi E, Leccese P, Olivieri I, Latanza L.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S58-62. Epub 2014 Jul 8.

PMID:
25005224
14.

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.

Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.

Am J Gastroenterol. 2009 Dec;104(12):3042-9. doi: 10.1038/ajg.2009.493. Epub 2009 Sep 1.

PMID:
19724267
15.

Favorable response to high-dose infliximab for refractory childhood uveitis.

Kahn P, Weiss M, Imundo LF, Levy DM.

Ophthalmology. 2006 May;113(5):860-4.e2. Epub 2006 Mar 20.

PMID:
16545455
16.

Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.

Martín-de-Carpi J, Pociello N, Varea V.

J Crohns Colitis. 2010 Nov;4(5):594-8. doi: 10.1016/j.crohns.2010.04.002. Epub 2010 May 1.

PMID:
21122566
17.

Safety and efficacy of adalimumab in pediatric patients with Crohn disease.

Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L.

J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):19-25. doi: 10.1097/MPG.0b013e318174e886.

PMID:
18607264
18.

Retrospective analysis of children with uveitis treated with infliximab.

Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N.

J AAPOS. 2008 Dec;12(6):611-3. doi: 10.1016/j.jaapos.2008.08.007. Epub 2008 Oct 19.

PMID:
18930672
19.

Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.

Brandse JF, Peters CP, Gecse KB, Eshuis EJ, Jansen JM, Tuynman HA, Löwenberg M, Ponsioen CY, van den Brink GR, DʼHaens GR; North Holland GUT Club.

Inflamm Bowel Dis. 2014 Feb;20(2):251-8. doi: 10.1097/01.MIB.0000438248.14218.1d.

PMID:
24378599
20.

Adalimumab for sight-threatening uveitis in Behçet's disease.

Mushtaq B, Saeed T, Situnayake RD, Murray PI.

Eye (Lond). 2007 Jun;21(6):824-5. Epub 2006 Apr 7.

PMID:
16601736
Items per page

Supplemental Content

Write to the Help Desk